Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DELTA 3 long-term extension of delgocitinib cream for chronic hand eczema
NL-OMON51146Phase 3Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of delgocitinib in chronic hand dermatitis (CHE), sponsored by LEO Pharma. Primary endpoint: Number of treatment-emergent adverse events. Started Jan 2022; status: active, not recruiting.
02
Drugs
delgocitinib
03
Conditions
chronic hand dermatitis (CHE)
Beyond the preview
Go deeper on NL-OMON51146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51146.